Uzroci trombocitopenije u oboljelih od bolesti COVID-19
| Autor: | Bežovan, Dora, Mitrović, Zdravko |
|---|---|
| Jazyk: | chorvatština |
| Rok vydání: | 2022 |
| Předmět: | |
| Zdroj: | Medicina Fluminensis : Medicina Fluminensis Volume 58 Issue 3 |
| ISSN: | 1848-820X 1847-6864 |
| Popis: | Trombocitopenija je česta u virusnim infekcijama, prisutna je u prosječno 18 % oboljelih od bolesti COVID-19, a obično je blaga (u rasponu od 100 do 150 × 10^9/L). Zastupljenija je među teže oboljelima i predstavlja neovisan čimbenik rizika za loš ishod i mortalitet. Trombocitopenija je rezultat smanjene proizvodnje i povećane potrošnje trombocita. Smanjenje proizvodnje trombocita može nastati zbog oštećenja hematopoetskih progenitora te zbog oštećenja kapilarne mreže pluća. Povećana je potrošnja trombocita zbog njihove hiperaktivacije i trombotske mikroangiopatije kod kritično bolesnih. U bolesti COVID-19 rjeđe se može razviti i imuna trombocitopenija (ITP) te trombocitopenija uzrokovana različitim lijekovima, uključujući i trombocitopeniju uzrokovanu heparinom (HIT). Thrombocytopenia is frequent in viral infections. Approximately 18% of COVID-19 patients have thrombocytopenia that is usually mild (ranging from 100 to 150 × 10^9/L). It is more common among critically ill whereby it is an independent risk factor for poor outcome and mortality. Both decreased production and increased consumption of platelets may contribute. Decreased platelet production may occur due to a damage to hematopoietic progenitors and capillary network of the lungs. The consumption of platelets is increased due to their hyperactivation and thrombotic microangiopathy. Immune thrombocytopenia (ITP) and drug-induced thrombocytopenia including heparin-induced thrombocytopenia (HIT) can also develop during COVID-19 treatment. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|